The FDA has approved Archimedes Pharma's Lazanda nasal spray for the management of breakthrough pain in adult cancer patients, according to a report by the FDA.
Breakthrough pain in cancer is an intense, sudden pain that is often unpredictable and debilitating and occurs despite otherwise appropriate opioid therapy, Archimedes Pharma reported.
During the rest of 2011, the company said Lazanda will be available through a Risk Evaluation and Mitigation Strategy program.
Read the FDA report on Lazanda.
Read the Archimedes Pharma release on Lazanda.
Related Articles on FDA Approvals:
FDA Clears New Version of PillCam for Esophageal Mucosa
Expected Approval of Minimally Invasive Aortic Devices Will Spark Boom
FDA Pressed to Speed Up Device OKs Before Fee Reauthorization